Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TACR1 | P25103 | 2/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9681362 | 0.74 | KMT2A (0.42) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7042662 | 0.73 | SIGMAR1 (0.42) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL10893088 | 0.67 | GRIN2B (0.38) | KMT2AHTTSMN1; SMN2MEN1 | |
| SCHEMBL8520514 | 0.67 | PIN1 (0.40) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL11425808 | 0.66 | POLB (0.58) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL5696701 | 0.63 | HTT (0.42) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL9732807 | 0.60 | TSHR (0.34) | KMT2AHTTTSHRTP53ALDH1A1 | |
| SCHEMBL3120601 | 0.59 | TSHR (0.36) | KMT2AHTTTSHRTP53ALDH1A1 | |
| SCHEMBL7316250 | 0.59 | KMT2A (0.56) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL5809783 | 0.59 | SIGMAR1 (0.54) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1450812-A4 | USE OF BENZOPYRANONES FOR TREATING OR PREVENTING A PRIMARY BRAIN CANCER OR A BRAIN METASTASIS | SIGNAL PHARM INC (US) | 2007-03-28 | — | — | EP | disclosed |
| US-7148252-B2 | Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis | SIGNAL PHARMACEUTICALS, LLC (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1450812-A2 | USE OF BENZOPYRANONES FOR TREATING OR PREVENTING A PRIMARY BRAIN CANCER OR A BRAIN METASTASIS | Signal Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20030149025-A1 | Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis | SIGNAL PHARMACEUTICALS, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003028652-A2 | USE OF BENZOPYRANONES FOR TREATING OR PREVENTING A PRIMARY BRAIN CANCER OR A BRAIN METASTASIS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149025-A1 | Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis | RB1, FOXK1, SKP1 | CHRM2 1163/4885CHRM4 2586/4885CHRM5 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.